Outlook Therapeutics
Update in progressOTLK (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on monoclonal antibodies for ophthalmic indications. Its lead candidate, ONS-5010, is an ophthalmic bevacizumab formulation in Phase III for wet age-related macular degeneration and other retinal diseases. The company has a collaboration with Cencora. It was formerly Oncobiologics, renamed in 2018, and was incorporated in 2010 in Iselin, New Jersey.
Company score
- Sentiment
- 0.43
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.31
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.27
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Robert Charles Jahr
- Founded2010
- Employees17
- Websiteoutlooktherapeutics.com
Identifiers
- ISINUS69012T3059
- FIGIBBG00469JRJ5
- CUSIP68235M105
- CIK0001649989